Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contract liabilities — Current portion by Year
Contract liabilities — Current portion ($M) ($M)
Vertex Pharmaceuticals Contract liabilities — Current portion: $172M in FY2025, down 16.9% from a year earlier.
Latest, FY2025
172
Period ended Dec 31, 2025
Change on a year earlier
-16.9%
207 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Revenue Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contract liabilities — Current portion ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 172 | -16.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 207 | +21.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 170 | +6.7% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 160 | -7.0% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 172 | -10.3% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 192 | +207.4% | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 62.3 | +150.2% | Form 10-K (filed 2021-02-11) ↗ |
| FY2018 | Dec 31, 2018 | 24.9 | – | Form 10-K (filed 2020-02-13) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contract liabilities — Current portion ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/contract-liab-cur
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.